Epsom PCN

A list of 61,343 features 18.7% aged 65+ alongside 11.1% Asian resident diversity

EPSOM PCN serves 61,343 registered patients across six practices. Those aged 65+ make up 18.7% (11,447 patients), compared with 18.3% in Epsom and Ewell, 18.8% in NHS Surrey Heartlands Integrated Care Board, and 17.9% in England. Patients aged 0–17 comprise 21.3% (13,085; borough 20.7%, ICB 20.4%, England 19.6%). Census data shows an 11.1% Asian or Asian British resident share (borough 11.4%, ICB 7.7%, England 9.6%), reaching 15.9% at Shadbolt Park House Surg. An unverified projection estimates 5.3% list growth to 2030 (borough 4.2%, ICB 4.9%, England 2.3%). Age figures reflect registered patients; ethnic shares reflect Census residents.

Deprivation is low overall, but Core20 patients concentrate in three practices

EPSOM PCN has low average deprivation at decile 8.6 (Epsom and Ewell 8.5; NHS Surrey Heartlands ICB 7.9; England 5.5). Its Core20 share is 0.8%, below Epsom and Ewell (2.0%), in line with NHS Surrey Heartlands ICB (0.8%) and below England (21.0%). However, Core20 patients concentrate unevenly: Fountain Practice has 2.25% (185 estimated patients) and Spring Street Surgery 1.18% (175), while three practices record 0.0%. Resident Core20 estimates (about 450) and practice sums (479) use different bases. Targeting proactive outreach to the two highest-volume practices may address concentrated deprivation.

PLUS groups and inclusion health

The PCN records 220 learning disability patients (0.3% vs Epsom and Ewell 0.5%, ICB 0.5%, England 0.6%) and 436 severe mental illness patients (0.7% vs England 1.0%). Catchment facilities include 34 care homes with 800 beds. Borough unpaid care is 8.0%, and rough sleeping was 0 in 2025. Recorded learning disability prevalence trails benchmarks; this does not prove under-detection, but register audits could test for unrecorded cases.

Severe mental illness: physical health checks

Severe mental illness recorded prevalence is 0.7% (England 1.0%). Annual blood pressure checks reached 90.6% (England 83.4%) and BMI recording reached 90.9% (England 82.1%).

Clinical focus: hypertension and lipids

Hypertension case-finding and control

Recorded hypertension prevalence is 14.2% (8,843 patients), below Epsom and Ewell (15.1%), NHS Surrey Heartlands Integrated Care Board (14.3%), and England (15.2%). QOF prevalence grew +1.4% over 2023 to 2025 (England +5.6%), yielding an unadjusted benchmark gap range of +403 to +499 patients. Meanwhile, 73.2% of hypertensive patients are treated to target (England 70.3%) and 71.5% aged under 80 reach target (England 67.8%). Lagging register growth alongside high treatment control is consistent with potential under-detection, which practice audits can test.

Lipids and statins

Among patients with QRISK ≥ 20%, 62.3% receive lipid-lowering therapy, exceeding Epsom and Ewell (61.0%) and NHS Surrey Heartlands Integrated Care Board (59.4%) but trailing England (63.6%). Over 2023 to 2025, treated patients increased by +7.0% (England +6.2%). Uptake trails England, indicating scope to review eligible high-risk patients.

In 2026, lipid-regulating drugs cost £2.40 per item across 67,084 prescribed items (£161,002 spend), matching Epsom and Ewell (£2.40) but exceeding England (£1.86). The PCN spends £36,225 more than at England's unit cost. Unit cost differences provide an indicator of prescribing mix across practices.

Clinical focus: respiratory, cancer register and children

Respiratory

COPD prevalence is 1.2% (726 patients; England 1.9%, Epsom and Ewell 1.1%), falling -4.3% over 2023 to 2025 (England +2.6%). Meanwhile, COPD 12-month reviews rose +20.3% over 2023 to 2025 (England +2.8%) to 85.5% (England 76.4%). Asthma prevalence is 6.1% (3,576 patients; England 6.6%), with 71.2% reviewed in the last 12 months (England 65.7%), leaving about 1,000 unreviewed patients. Asthma prescribing for ages 5–19 is 960 items per 1,000 population (England 1,488).

Cancer register and children's immunisation

Cancer prevalence is 4.2% (2,633 patients; England 3.8%). In Q1 2025/26, 6-in-1 immunisation at 12 months was 97.0% and MMR dose 1 at age 5 reached 96.1%. However, MMR dose 2 coverage was 89.4% (6.7 pp below dose 1 and 5.6 pp below the 95.0% target; denominator 179), and 4-in-1 pre-school booster coverage was 88.8% (6.2 pp below the 95.0% target).

Early cancer diagnosis

In 2022, 61.4% of staged cancers across NHS Surrey Heartlands ICB were diagnosed at stage 1 or 2 (2,955 of 4,810 staged; 67.7% known-stage share), above England (55.3%) but below the 75.0% national ambition, equating to about 650 extra early-stage diagnoses annually. Early-stage detection was 48.1% for bowel and 33.2% for lung cancer. Locally, PCN cervical screening coverage for women aged 25 to 49 is 67.5% (ICB 69.3%, England 66.8%), ranging from 63.5% at Derby Medical Centre and 64.0% at Fountain Practice to 74.5% at St Stephens House Surgery. Systematically auditing non-responders could help lift screening coverage and support earlier presentation.

Cancer waits, diagnostics and community services

Cancer waits and diagnostics, Jul 2026 (provisional)

In provisional July 2026 provider data, Epsom and St Helier University Hospitals NHS Trust achieved 86.8% on the 62-day cancer referral to treatment standard, exceeding the 85.0% standard, St George's University Hospitals NHS Foundation Trust (83.0%), Kingston and Richmond NHS Foundation Trust (75.3%), NHS Surrey and Sussex ICB (71.5%), and England (71.2%). The trust met the 28-day faster diagnosis standard at 89.7% (standard 75.0%) and the 31-day combined standard at 99.2% (standard 96.0%). Diagnostic 6+ week waits were 0.3% for MRI and 1.1% for CT, compared to calculated England rates of 21.4% and 9.9%.

Practice phone access and vaccination achievement vary widely across the six constituent practices

In 2025/26, overall QOF achievement ranged from 88.6% at Shadbolt Park House Surg to 98.9% at St Stephens House Surgery. Clinical domain achievement reached 95.7% at Shadbolt Park House Surg, yet vaccination and immunisation achievement varied by 60.7 pp (32.8% at Shadbolt Park House Surg to 93.5% at St Stephens House Surgery).

13 of 25 measures trail England's three-year change, led by heart failure reviews

Across 25 measures, 13 trail England's three-year change over 2023 to 2025. The widest lag is in heart failure reviews, which fell 13.5% (England +8.7%). Disease registers fell for dementia by 4.3% (England +6.0%), COPD by 4.3% (England +2.6%), and stroke by 2.4% (England +2.3%). Conversely, routine care saw relative strengths: COPD reviews rose 20.3% (England +2.8%), asthma reviews rose 9.7% (England +4.4%), and under-80 blood pressure control rose 8.5% (England +3.2%).

What the data can't tell us: gaps and local assets

Options for the PCN

Each option in full

Provenance and audit trail

Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.

Data sources

Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.

Methods, data-quality notes and limitations